PMID- 31665730
OWN - NLM
STAT- MEDLINE
DCOM- 20200911
LR  - 20200911
IS  - 1421-9832 (Electronic)
IS  - 1018-8665 (Linking)
VI  - 236
IP  - 3
DP  - 2020
TI  - Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and 
      Efficacy in Children.
PG  - 191-198
LID - 10.1159/000503062 [doi]
AB  - INTRODUCTION: Psoriasis is a chronic, multifactorial, inflammatory disorder, with 
      an estimated prevalence of 0.71% in children. The commonly used therapeutic 
      agents target the underlying inflammation. Tofacitinib has demonstrated efficacy 
      in adult psoriasis. AIM: To study the efficacy, safety, and tolerability of 
      tofacitinib in pediatric patients with moderate to severe chronic plaque 
      psoriasis. METHODS: The study included children aged between 8 and 17 years, with 
      moderate to severe psoriasis, given tofacitinib 5 mg orally twice daily for at 
      least 36 weeks. The clinical response was estimated using the Psoriasis Area and 
      Severity Index (PASI) score, Physician's Global Assessment (PGA), and the 
      Children's Dermatology Life Quality Index (CDLQI). The incidence and severity of 
      adverse events (AEs) were meticulously recorded in each case. RESULTS: A total of 
      47 patients, with a median age of 12.3 years, completed the study. At week 12, 
      55.32% achieved PASI 75, and 70.21% at week 36. PGA of clear or almost clear 
      responses at week 12 were 59.57 and 65.96%, -respectfully, at week 36. Relatively 
      few and mostly minor -adverse effects were noted. No severe AEs were reported. 
      -Conclusion: The treatment with tofacitinib was safe and well tolerated, and led 
      to significant improvement of their disease and quality of life as reflected in 
      CDLQI scores. However, the results need to be validated in larger multicenter 
      trials.
CI  - (c) 2019 S. Karger AG, Basel.
FAU - AlMutairi, Nawaf
AU  - AlMutairi N
AD  - Department of Medicine, Faculty of Medicine, Kuwait University, Farwaniya, 
      Kuwait, nalmut@usa.net.
FAU - Nour, Tarek
AU  - Nour T
AD  - Department of Dermatology, Farwaniya Hospital, Farwaniya, Kuwait.
LA  - eng
PT  - Journal Article
DEP - 20191030
PL  - Switzerland
TA  - Dermatology
JT  - Dermatology (Basel, Switzerland)
JID - 9203244
RN  - 0 (Piperidines)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Pyrimidines)
RN  - 0 (Pyrroles)
RN  - 87LA6FU830 (tofacitinib)
SB  - IM
MH  - Adolescent
MH  - Child
MH  - Female
MH  - Humans
MH  - Male
MH  - Piperidines/*therapeutic use
MH  - Protein Kinase Inhibitors/*therapeutic use
MH  - Psoriasis/*drug therapy
MH  - Pyrimidines/*therapeutic use
MH  - Pyrroles/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - JAK inhibitors
OT  - Psoriasis
OT  - Tofacitinib
EDAT- 2019/10/31 06:00
MHDA- 2020/09/12 06:00
CRDT- 2019/10/31 06:00
PHST- 2019/05/19 00:00 [received]
PHST- 2019/08/29 00:00 [accepted]
PHST- 2019/10/31 06:00 [pubmed]
PHST- 2020/09/12 06:00 [medline]
PHST- 2019/10/31 06:00 [entrez]
AID - 000503062 [pii]
AID - 10.1159/000503062 [doi]
PST - ppublish
SO  - Dermatology. 2020;236(3):191-198. doi: 10.1159/000503062. Epub 2019 Oct 30.